Dottikon Es (DESN) H2 24/25 earnings summary

Executive summary

• Net sales increased 18.1% year-over-year to CHF 385.2 million, resuming growth with new manufacturing capacity operational.

• EBITDA rose 27.2% to CHF 140.5 million, with margin improving to 36.5% from 33.9% year-over-year.

• Net income grew 30.9% to CHF 105.6 million, with a net income margin of 27.4%.

• Workforce expanded 9.2% to 793 FTEs, with end-of-year headcount near 860.

Financial highlights

• EBIT increased 31.8% to CHF 118.4 million, with margin at 30.7%.

• Cash flow from operating activities declined 6.8% to CHF 95.7 million, mainly due to strong, not yet cash-effective Q4 sales.

• Cash and cash equivalents plus current financial assets totaled CHF 197.8 million at year-end.

• Equity ratio stood at 73.5%; non-current interest-bearing financial liabilities were CHF 130 million.

• Capital expenditures remained high, with CHF 127.1 million outflow for investing activities.

Outlook and guidance

• Net sales for 2025/26 expected to exceed prior year, supported by new plant capacity coming online.

• Ongoing high investment planned to nearly double manufacturing capacity at the Dottikon site.

• Focus remains on safety, reliability, high quality, flexibility, and speed to strengthen strategic partner position.

• Performance Chemicals unit to develop new products for non-pharma markets to diversify growth.